Skip to main content

Table 3 Univariate analysis for association of baseline characteristics and therapeutic response with PFS and OS from start of PLD.

From: Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial

Characteristics

Number of patients

Median PFS, months

P value

Median OS, months

P value

All

129

5.8

 

14.2

 

Age

     

   < 63

64

5.7

0.147

12.5

0.776

   ≥63

64

7.3

 

14.6

 

Age

     

   < 50

17

4.0

0.247

16.6

0.880

   ≥50

112

6.0

 

14.2

 

No. cardiac risk factors

     

   1 - 2

88

5.3

0.997

14.5

0.163

   ≥3

41

6.4

 

11.1

 

No. metastatic sites

     

   1-3

99

7.1

0.021

15.3

< 0.001

   4-7

30

3.6

 

6.0

 

Metastatic site

     

   Visceral

92

5.4

0.034

12.5

0.618

   Nonvisceral

37

9.8

 

14.3

 

Prior endocrine therapy

     

   No

33

5.4

0.305

14.8

0.061

   Yes

96

6.0

 

12.4

 

No. of prior chemos+

     

   0 - 3

95

7.3

0.001

14.5

0.01

   ≥4

34

5.0

 

10.1

 

Prior anthracycline

     

   No

52

7.8

0.104

15.1

0.057

   Yes

77

5.7

 

10.1

 

Prior taxane

     

   No

56

7.8

0.036

14.3

0.392

   Yes

73

5.4

 

12.5

 

Response

     

   CR/PR

34

10.0

<

17.5

< 0.001

   SD

24

11.9

0.001

24.6

 

   PD

62

2.8

 

8.6

 

   NE

9

2.4

 

3.0

 

PLD extension*

     

   6 cycles, no extension

31

9.8

0.466

21.3

0.516

   > 6 cycles

17

10.9

 

24.2

 
  1. *Patients who achieved SD, PR or CR after scheduled PLD (i.e., 6 cycles). +Adjuvant chemotherapy was counted as prior therapy line.